Skip to main content
Resverlogix Corp. logo

Resverlogix Corp. — Investor Relations & Filings

Ticker · RVX ISIN · CA76128M1086 LEI · 529900VI46SAPCOSH758 TSX Real estate activities
Open in API
Filings indexed 195 across all filing types
Latest filing 2020-09-26 Regulatory Filings
Country CA Canada
Listing TSX RVX

About Resverlogix Corp.

https://www.resverlogix.com/

Resverlogix Corp. is a late-stage clinical biotechnology company specializing in the development of epigenetic therapies for chronic illnesses. The company's core scientific focus involves regulating the expression of disease-causing genes. Its lead drug candidate is Apabetalone, a small molecule inhibitor currently being advanced through clinical programs, including the BETonMACE trial. Apabetalone is primarily targeted toward treating cardiovascular diseases and complications associated with diabetes mellitus. Resverlogix aims to provide novel science and value-based health solutions to key stakeholders, including pharmaceutical companies, physicians, and health payer groups.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from Resverlogix providing an update on the extension of its filing calendar for interim financial statements and related MD&A for the three months ended July 31, 2020. It mentions the granting of a management cease trade order (MCTO) due to late filing of these interim filings. The document does not contain the actual interim financial statements or MD&A, but rather an announcement about the delay and expected filing date. The document length is 4434 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about filing delays and related regulatory actions, not the interim report itself.
2020-09-26 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the publication of a scientific article in a peer-reviewed journal about the therapeutic potential of BET inhibition. It discusses research highlights, publication background, and company information. There is no financial data, regulatory filing, or report content such as annual or quarterly financial statements. The document is an announcement of a publication rather than a financial or regulatory report. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories.
2020-09-15 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a news release from Resverlogix providing an update on the extension of its filing calendar and confirming that its annual financial statements and related documents for the year ended April 30, 2020, have been filed on SEDAR. It also discusses delays in filing interim financial statements and the application for a management cease trade order due to these delays. The document does not contain the actual financial statements or MD&A but rather announces the status and timing of filings and regulatory compliance matters. It is a regulatory announcement about filings and compliance rather than the filings themselves. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and update on filing status.
2020-09-12 English
52-109F1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F1 Certification of Annual Filings Full Certificate by the CFO of Resverlogix Corp. It certifies the review and fair presentation of the annual filings for the financial year ended April 30, 2020. The document is primarily an officer certification regarding the accuracy and completeness of the annual filings, including the MD&A and financial statements. It does not contain the actual financial statements or detailed financial data itself, but rather attests to their correctness and the effectiveness of internal controls. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the Annual Report (10-K) or Management Discussion & Analysis (MDA). The document length is 4536 characters, which is relatively short and consistent with a certification letter rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-09-12 English
52-109F1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F1 Certification of Annual Filings Full Certificate signed by the CEO. It certifies the review and fairness of the annual filings for the financial year ended April 30, 2020, including the annual financial statements and MD&A. The document is primarily an officer certification attesting to the accuracy and completeness of the annual filings and the effectiveness of disclosure controls and internal controls over financial reporting. It does not contain the actual financial statements or substantive financial data itself, but rather certifies the annual filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the Annual Report (10-K) or other financial reports. The document length is 4563 characters, which is relatively short and consistent with a certification letter rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-09-12 English
Annual MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled "MANAGEMENT'S DISCUSSION & ANALYSIS – Q4 2020" and contains detailed discussion of the company's financial position, operations, forward-looking statements, non-IFRS measures, going concern considerations, and an overview of the company's business and clinical trials. The text references the fiscal period ended April 30, 2020, and includes substantive financial and operational analysis typical of a Management Discussion and Analysis (MD&A) section. There is no indication that this is merely an announcement or a certification. The length (15,000 characters) and content confirm it is a comprehensive report rather than a brief announcement. Therefore, the document fits the category of Management Reports (MDA).
2020-09-12 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.